Role of the Immune System and the Circadian Rhythm in the Pathogenesis of Chronic Pancreatitis: Establishing a Personalized Signature for Improving the Effect of Immunotherapies for Chronic Pancreatitis.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
entrez:
25
8
2020
pubmed:
25
8
2020
medline:
3
8
2021
Statut:
ppublish
Résumé
Pancreatitis, in both acute and chronic forms, poses a major therapeutic challenge and is associated with great morbidity and several complications. The nature of pancreatic injury in chronic pancreatitis (CP) and the wide range of causative processes that lead to CP have made effective therapy a true unmet need. Multiple physiological, genetic, environmental, and behavioral factors contribute to the development of CP. As a result, several fields of research are aimed at identifying and addressing the factors that contribute to pancreatic injury. In this article, we review the current understanding of the pathogenesis and natural history of CP. We focus on the autonomous nervous system, immune system, and role of a chronobiological therapeutic approach to alleviate symptoms and prevent or reverse pancreatic injury associated with CP. We aim to demonstrate that individualizing chronopharmacological treatments for CP is a promising direction for future treatment using immune, nervous, and circadian systems.
Identifiants
pubmed: 32833942
doi: 10.1097/MPA.0000000000001626
pii: 00006676-202009000-00003
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1024-1032Références
Kleeff J, Whitcomb DC, Shimosegawa T, et al. Chronic pancreatitis. Nat Rev Dis Primers. 2017;3:17060.
Majumder S, Chari ST. Chronic pancreatitis. Lancet. 2016;387:1957–1966.
Wang LW, Li ZS, Li SD, et al. Prevalence and clinical features of chronic pancreatitis in China: a retrospective multicenter analysis over 10 years. Pancreas. 2009;38:248–254.
Yadav D, Timmons L, Benson JT, et al. Incidence, prevalence, and survival of chronic pancreatitis: a population-based study. Am J Gastroenterol. 2011;106:2192–2199.
Otsuki M. Chronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems. J Gastroenterol. 2003;38:315–326.
Wilcox CM, Sandhu BS, Singh V, et al. Racial differences in the clinical profile, causes, and outcome of chronic pancreatitis. Am J Gastroenterol. 2016;111:1488–1496.
Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144:1252–1261.
Lowenfels AB, Maisonneuve P, Grover H, et al. Racial factors and the risk of chronic pancreatitis. Am J Gastroenterol. 1999;94:790–794.
Lévy P, Domínguez-Muñoz E, Imrie C, et al. Epidemiology of chronic pancreatitis: burden of the disease and consequences. United European Gastroenterol J. 2014;2:345–354.
Lankisch PG, Löhr-Happe A, Otto J, et al. Natural course in chronic pancreatitis. Pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease. Digestion. 1993;54:148–155.
Miyake H, Harada H, Ochi K, et al. Prognosis and prognostic factors in chronic pancreatitis. Dig Dis Sci. 1989;34:449–455.
Lowenfels AB, Maisonneuve P, Cavallini G, et al. Prognosis of chronic pancreatitis: an international multicenter study. International Pancreatitis Study Group. Am J Gastroenterol. 1994;89:1467–1471.
Dumonceau JM, Vonlaufen A. Pancreatic endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy. 2007;39:124–130.
Domínguez-Muñoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep. 2007;9:116–122.
van Esch AA, Wilder-Smith OH, Jansen JB, et al. Pharmacological management of pain in chronic pancreatitis. Dig Liver Dis. 2006;38:518–526.
Alexakis N, Halloran C, Raraty M, et al. Current standards of surgery for pancreatic cancer. Br J Surg. 2004;91:1410–1427.
Büchler MW, Martignoni ME, Friess H, et al. A proposal for a new clinical classification of chronic pancreatitis. BMC Gastroenterol. 2009;9:93.
Steer ML, Waxman I, Freedman S. Chronic pancreatitis. N Engl J Med. 1995;332:1482–1490.
Sahel J, Sarles H. Modifications of pure human pancreatic juice induced by chronic alcohol consumption. Dig Dis Sci. 1979;24:897–905.
Ulmasov B, Xu Z, Talkad V, et al. Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. Am J Physiol Gastrointest Liver Physiol. 2010;299:G70–G80.
Criscimanna A, Coudriet GM, Gittes GK, et al. Activated macrophages create lineage-specific microenvironments for pancreatic acinar- and β-cell regeneration in mice. Gastroenterology. 2014;147:1106–1118.e11.
Zhang H, Neuhöfer P, Song L, et al. IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. J Clin Invest. 2013;123:1019–1031.
Apte M, Haber P, Darby S, et al. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 1999;44:534–541.
Omary MB, Lugea A, Lowe AW, et al. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest. 2007;117:50–59.
Komar HM, Serpa G, Kerscher C, et al. Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo. Sci Rep. 2017;7:1787.
Xue J, Sharma V, Hsieh MH, et al. Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. Nat Commun. 2015;6:7158.
Hunger RE, Mueller C, Z'Graggen K, et al. Cytotoxic cells are activated in cellular infiltrates of alcoholic chronic pancreatitis. Gastroenterology. 1997;112:1656–1663.
Schmitz-Winnenthal H, Pietsch DH, Schimmack S, et al. Chronic pancreatitis is associated with disease-specific regulatory T-cell responses. Gastroenterology. 2010;138:1178–1188.
Grundsten M, Liu GZ, Permert J, et al. Increased central memory T cells in patients with chronic pancreatitis. Pancreatology. 2005;5:177–182.
Roberts HR, Smartt HJ, Greenhough A, et al. Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation. Carcinogenesis. 2011;32:1741–1747.
Hasan S, Satake M, Dawson DW, et al. Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas. 2008;37:121–127.
Schlosser W, Schlosser S, Ramadani M, et al. Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas. 2002;25:26–30.
Silva A, Weber A, Bain M, et al. COX-2 is not required for the development of murine chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2011;300:G968–G975.
Reding T, Bimmler D, Perren A, et al. A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. Gut. 2006;55:1165–1173.
Polito F, Bitto A, Irrera N, et al. Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis. Br J Pharmacol. 2010;161:1002–1011.
Aoki H, Ohnishi H, Hama K, et al. Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines. Am J Physiol Cell Physiol. 2007;292:C259–C268.
Bai H, Chen X, Zhang L, et al. The effect of sulindac, a non-steroidal anti-inflammatory drug, attenuates inflammation and fibrosis in a mouse model of chronic pancreatitis. BMC Gastroenterol. 2012;12:115.
Suzuki S, Toyabe S, Moroda T, et al. Circadian rhythm of leucocytes and lymphocytes subsets and its possible correlation with the function of the autonomic nervous system. Clin Exp Immunol. 1997;110:500–508.
Buscher HC, van Goor H, Sweep CG, et al. Increased sympathetic activity in chronic pancreatitis patients is associated with hyperalgesia. J Pain Palliat Care Pharmacother. 2010;24:362–366.
Rosa-e-Silva L, Oliveira RB, Troncon LE, et al. Autonomic nervous function in alcohol-related chronic pancreatitis. Pancreas. 2000;20:361–366.
van Westerloo DJ, Giebelen IA, Florquin S, et al. The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. Gastroenterology. 2006;130:1822–1830.
Kraft CS, Hewlett AL, Koepsell S, et al. The use of TKM-100802 and convalescent plasma in 2 patients with ebola virus disease in the United States. Clin Infect Dis. 2015;61:496–502.
Juel J, Brock C, Olesen SS, et al. Acute physiological and electrical accentuation of vagal tone has no effect on pain or gastrointestinal motility in chronic pancreatitis. J Pain Res. 2017;10:1347–1355.
Buscher HC, Lenders JW, Wilder-Smith OH, et al. Bilateral thoracoscopic splanchnicectomy for pain in patients with chronic pancreatitis impairs adrenomedullary but not noradrenergic sympathetic function. Surg Endosc. 2012;26:2183–2188.
Winsö O, Kral J, Wang W, et al. Thoracic epidural anaesthesia reduces insulin resistance and inflammatory response in experimental acute pancreatitis. Ups J Med Sci. 2018;123:207–215.
Demir IE, Friess H, Ceyhan GO. Neural plasticity in pancreatitis and pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2015;12:649–659.
Li C, Zhu Y, Shenoy M, et al. Anatomical and functional characterization of a duodeno-pancreatic neural reflex that can induce acute pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2013;304:G490–G500.
Zhou H, Gao J, Zou D, et al. Effect of octreotide on enteric motor neurons in experimental acute necrotizing pancreatitis. PLoS One. 2012;7:e52163.
Demir IE, Wang K, Tieftrunk E, et al. Neuronal plasticity in chronic pancreatitis is mediated via the neurturin/GFRα2 axis. Am J Physiol Gastrointest Liver Physiol. 2012;303:G1017–G1028.
Tryliskyy Y, Bryce GJ. Role of heart rate variability in predicting post-endoscopic retrograde cholangiopancreatography pancreatitis. Acta Gastroenterol Belg. 2016;79:429–434.
Vieira E, Burris TP, Quesada I. Clock genes, pancreatic function, and diabetes. Trends Mol Med. 2014;20:685–693.
Buijs RM, Escobar C, Swaab DF. Chapter 15 - The circadian system and the balance of the autonomic nervous system. In: Buijs RM, Swaab DF, eds. Handbook of Clinical Neurology vol. 117. Amsterdam, The Netherlands: Elsevier B.V; 2013:173–191.
Dumbell R, Matveeva O, Oster H. Circadian Clocks, Stress, and Immunity. Front Endocrinol (Lausanne). 2016;7:37.
Panda S, Antoch MP, Miller BH, et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell. 2002;109:307–320.
Jiang W, Wan R. It is about time: circadian clock in the pancreas. Pancreat Disord Ther. 2015;5:1000155.
Mazzoccoli G, Pazienza V, Vinciguerra M. Clock genes and clock-controlled genes in the regulation of metabolic rhythms. Chronobiol Int. 2012;29:227–251.
Rana S, Munawar M, Shahid A, et al. Deregulated expression of circadian clock and clock-controlled cell cycle genes in chronic lymphocytic leukemia. Mol Biol Rep. 2014;41:95–103.
Zhang EE, Kay SA. Clocks not winding down: unravelling circadian networks. Nat Rev Mol Cell Biol. 2010;11:764–776.
Li S, Lin JD. Molecular control of circadian metabolic rhythms. J Appl Physiol (1985). 2009;107:1959–1964.
Huang W, Ramsey KM, Marcheva B, et al. Circadian rhythms, sleep, and metabolism. J Clin Invest. 2011;121:2133–2141.
Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci. 2012;35:445–462.
Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517–549.
Kalsbeek A, van der Spek R, Lei J, et al. Circadian rhythms in the hypothalamo-pituitary-adrenal (HPA) axis. Mol Cell Endocrinol. 2012;349:20–29.
Sakamoto K, Nagase T, Fukui H, et al. Multitissue circadian expression of rat period homolog (rPer2) mRNA is governed by the mammalian circadian clock, the suprachiasmatic nucleus in the brain. J Biol Chem. 1998;273:27039–27042.
Husse J, Eichele G, Oster H. Synchronization of the mammalian circadian timing system: light can control peripheral clocks independently of the SCN clock: alternate routes of entrainment optimize the alignment of the body's circadian clock network with external time. Bioessays. 2015;37:1119–1128.
Saini C, Brown SA, Dibner C. Human peripheral clocks: applications for studying circadian phenotypes in physiology and pathophysiology. Front Neurol. 2015;6:95.
Mühlbauer E, Wolgast S, Finckh U, et al. Indication of circadian oscillations in the rat pancreas. FEBS Lett. 2004;564:91–96.
Mühlbauer E, Gross E, Labucay K, et al. Loss of melatonin signalling and its impact on circadian rhythms in mouse organs regulating blood glucose. Eur J Pharmacol. 2009;606:61–71.
Pulimeno P, Mannic T, Sage D, et al. Autonomous and self-sustained circadian oscillators displayed in human islet cells. Diabetologia. 2013;56:497–507.
Vieira E, Marroquí L, Figueroa AL, et al. Involvement of the clock gene Rev-erb alpha in the regulation of glucagon secretion in pancreatic alpha-cells. PLoS One. 2013;8:e69939.
Allaman-Pillet N, Roduit R, Oberson A, et al. Circadian regulation of islet genes involved in insulin production and secretion. Mol Cell Endocrinol. 2004;226:59–66.
Sadacca LA, Lamia KA, deLemos AS, et al. An intrinsic circadian clock of the pancreas is required for normal insulin release and glucose homeostasis in mice. Diabetologia. 2011;54:120–124.
Marcheva B, Ramsey KM, Buhr ED, et al. Disruption of the CLOCK components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature. 2010;466:627–631.
Xiao W, Jiang W, Shen J, et al. Retinoic acid ameliorates pancreatic fibrosis and inhibits the activation of pancreatic stellate cells in mice with experimental chronic pancreatitis via suppressing the Wnt/β-catenin signaling pathway. PLoS One. 2015;10:e0141462.
Garaulet M, Lee YC, Shen J, et al. Genetic variants in human CLOCK associate with total energy intake and cytokine sleep factors in overweight subjects (GOLDN population). Eur J Hum Genet. 2010;18:364–369.
Woon PY, Kaisaki PJ, Bragança J, et al. Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes. Proc Natl Acad Sci U S A. 2007;104:14412–14417.
Englund A, Kovanen L, Saarikoski ST, et al. NPAS2 and PER2 are linked to risk factors of the metabolic syndrome. J Circadian Rhythms. 2009;7:5.
Liu C, Li H, Qi L, et al. Variants in GLIS3 and CRY2 are associated with type 2 diabetes and impaired fasting glucose in Chinese Hans. PLoS One. 2011;6:e21464.
Scheer FA, Hilton MF, Mantzoros CS, et al. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A. 2009;106:4453–4458.
Guo Y, Rong Y, Huang X, et al. Shift work and the relationship with metabolic syndrome in Chinese aged workers. PLoS One. 2015;10:e0120632.
Pan A, Schernhammer ES, Sun Q, et al. Rotating night shift work and risk of type 2 diabetes: two prospective cohort studies in women. PLoS Med. 2011;8:e1001141.
Garaulet M, Lee YC, Shen J, et al. CLOCK genetic variation and metabolic syndrome risk: modulation by monounsaturated fatty acids. Am J Clin Nutr. 2009;90:1466–1475.
Fedorov AA, Oranskiĭ IE, Chudinova OA, et al. [Chronopathology and chronotherapy of chronic pancreatitis]. [Article in Russian]. Vopr Kurortol Fizioter Lech Fiz Kult. 2007;13–16.
Jaworek J, Konturek SJ, Tomaszewska R, et al. The circadian rhythm of melatonin modulates the severity of caerulein-induced pancreatitis in the rat. J Pineal Res. 2004;37:161–170.
Bovo P, Cataudella G, Di Francesco V, et al. Intraluminal gastric pH in chronic pancreatitis. Gut. 1995;36:294–298.
Gale JE, Cox HI, Qian J, et al. Disruption of circadian rhythms accelerates development of diabetes through pancreatic beta-cell loss and dysfunction. J Biol Rhythms. 2011;26:423–433.
Vieira E, Marroquí L, Batista TM, et al. The clock gene Rev-erbα regulates pancreatic β-cell function: modulation by leptin and high-fat diet. Endocrinology. 2012;153:592–601.
Gangwisch JE. Epidemiological evidence for the links between sleep, circadian rhythms and metabolism. Obes Rev. 2009;10(suppl 2):37–45.
Barbadoro P, Santarelli L, Croce N, et al. Rotating shift-work as an independent risk factor for overweight Italian workers: a cross-sectional study. PLoS One. 2013;8:e63289.
Karlsson B, Knutsson A, Lindahl B. Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27,485 people. Occup Environ Med. 2001;58:747–752.
Donga E, van Dijk M, van Dijk JG, et al. A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J Clin Endocrinol Metab. 2010;95:2963–2968.
Spiegel K, Tasali E, Leproult R, et al. Effects of poor and short sleep on glucose metabolism and obesity risk. Nat Rev Endocrinol. 2009;5:253–261.
Schroeder AM, Colwell CS. How to fix a broken clock. Trends Pharmacol Sci. 2013;34:605–619.
Solt LA, Wang Y, Banerjee S, et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012;485:62–68.
Owens B. Obesity: heavy sleepers. Nature. 2013;497:S8–S9.
Niwa F, Kuriyama N, Nakagawa M, et al. Circadian rhythm of rest activity and autonomic nervous system activity at different stages in Parkinson's disease. Auton Neurosci. 2011;165:195–200.
Perciaccante A, Fiorentini A, Paris A, et al. Circadian rhythm of the autonomic nervous system in insulin resistant subjects with normoglycemia, impaired fasting glycemia, impaired glucose tolerance, type 2 diabetes mellitus. BMC Cardiovasc Disord. 2006;6:19.
Kenney MJ, Ganta CK. Autonomic nervous system and immune system interactions. Compr Physiol. 2014;4:1177–1200.
Chowdhury D, Wang C, Lu AP, et al. Understanding quantitative circadian regulations are crucial towards advancing chronotherapy. Cell. 2019;8:883.
Kaur G, Phillips C, Wong K, et al. Timing is important in medication administration: a timely review of chronotherapy research. Int J Clin Pharmacol. 2013;35:344–358.
Halberg F, Haus E, Cardoso SS, et al. Toward a chronotherapy of neoplasia: tolerance of treatment depends upon host rhythms. Experientia. 1973;29:909–934.
Lévi F, Focan C, Karaboué A, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 2007;59:1015–1035.
Lauriola M, Enuka Y, Zeisel A, et al. Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nat Commun. 2014;5:5073.
Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med. 1985;313:1315–1322.
Stranges PM, Drew AM, Rafferty P, et al. Treatment of hypertension with chronotherapy: is it time of drug administration? Ann Pharmacother. 2015;49:323–334.
Portaluppi F, Smolensky MH. Circadian rhythm and environmental determinants of blood pressure regulation in normal and hypertensive conditions. In: White WB, ed. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. Totowa, NJ: Humana Press; 2001:79–138.
Hermida RC, Ayala DE, Portaluppi F. Circadian variation of blood pressure: the basis for the chronotherapy of hypertension. Adv Drug Deliv Rev. 2007;59:904–922.
Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic hypertension in Europe trial investigators. JAMA. 1999;282:539–546.
Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156–161.
Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168:2340–2346.
Kikuya M, Ohkubo T, Asayama K, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension. 2005;45:240–245.
Katz FH, Romfh P, Smith JA. Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man. J Clin Endocrinol Metab. 1975;40:125–134.
Bartter FC, Chan JC, Simpson HW. Chronobiological aspect of plasma renin activity, plasma aldosterone and urinary electrolytes. In Krieger DT, ed. Endocrine Rhythms. New York, NY: Raven Press;1979:225–245.
Cugini P, Manconi R, Serdoz R, et al. Rhythm characteristics of plasma renin, aldosterone and cortisol in five subtypes of mesor-hypertension. J Endocrinol Invest. 1980;3:143–147.
Angeli A, Gatti G, Masera R. Chronobiology of the hypothalamic-pituitary-adrenal and renin-angiotensin-aldosterone systems. In: Touitou Y, Haus E, eds. Biologic Rhythms in Clinical and Laboratory Medicine. Berlin, Germany: Springer Berlin Heidelberg; 1992:292–314.
Hermida RC, Ayala DE, Fernández JR, et al. Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am J Hypertens. 2011;24:383–391.
Spies CM, Cutolo M, Straub RH, et al. Prednisone chronotherapy. Clin Exp Rheumatol. 2011;29(5 suppl 68):S42–S45.
Beltrametti SP, Ianniello A, Ricci C. Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review. Ther Clin Risk Manag. 2016;12:1763–1776.
Cutolo M. Glucocorticoids and chronotherapy in rheumatoid arthritis. RMD Open. 2016;2:e000203.
Wang X, Yan X, Wang F, et al. Role of methotrexate chronotherapy in collagen-induced rheumatoid arthritis in rats. Z Rheumatol. 2018;77:249–255.
To H, Yoshimatsu H, Tomonari M, et al. Methotrexate chronotherapy is effective against rheumatoid arthritis. Chronobiol Int. 2011;28:267–274.
Buurma M, van Diemen JJK, Thijs A, et al. Circadian rhythm of cardiovascular disease: the potential of chronotherapy with aspirin. Front Cardiovasc Med. 2019;6:84.
Bowles NP, Thosar SS, Herzig MX, et al. Chronotherapy for hypertension. Curr Hypertens Rep. 2018;20:97.
Almirall J, Comas L, Martínez-Ocaña JC, et al. Effects of chronotherapy on blood pressure control in non-dipper patients with refractory hypertension. Nephrol Dial Transplant. 2012;27:1855–1859.
Lévi F. Chronopharmacology of Anticancer Agents. In: Redfern PH, Lemmer B, eds. Physiology and Pharmacology of Biological Rhythms. Berlin, Germany: Springer Berlin Heidelberg; 1997:299–331.
Lévi F, Giacchetti S, Adam R, et al. Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Eur J Cancer. 1995;31A:1264–1270.
Lévi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001;2:307–315.
Li XM, Mohammad-Djafari A, Dumitru M, et al. A circadian clock transcription model for the personalization of cancer chronotherapy. Cancer Res. 2013;73:7176–7188.
Ilan Y. Advanced tailored randomness: a novel approach for improving the efficacy of biological systems. J Comput Biol. 2020;27:20–29.
Ilan Y. Why targeting the microbiome is not so successful: can randomness overcome the adaptation that occurs following gut manipulation? Clin Exp Gastroenterol. 2019;12:209–217.
Ilan Y. β-Glycosphingolipids as mediators of both inflammation and immune tolerance: a manifestation of randomness in biological systems. Front Immunol. 2019;10:1143.
Ilan Y. Randomness in microtubule dynamics: an error that requires correction or an inherent plasticity required for normal cellular function? Cell Biol Int. 2019;43:739–748.
Ilan Y. Generating randomness: making the most out of disordering a false order into a real one. J Transl Med. 2019;17:49.
Rensing N, Han L, Wong M. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex. Epilepsia. 2015;56:1088–1097.
Ferriols-Lisart R, Ferriols-Lisart F. Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatol Int. 2015;35:1193–1210.
Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24–30.
Strik A, Berends S, Mould D, et al. DOP56 dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial. J Crohns Colitis. 2019;13(suppl 1):S063.abstract.
Weiner WJ, Koller WC, Perlik S, et al. Drug holiday and management of Parkinson disease. Neurology. 1980;30:1257–1261.
Toni T, Tidor B. Combined model of intrinsic and extrinsic variability for computational network design with application to synthetic biology. PLoS Comput Biol. 2013;9:e1002960.
Orsini C, Dankulov MM, Colomer-de-Simón P, et al. Quantifying randomness in real networks. Nat Commun. 2015;6:8627.
Ghanjal A, Motaqi M, Arab Z, et al. Force variability in the short- and long-term type 2 diabetes mellitus. J Med Signals Sens. 2019;9:50–58.
Ilan Y. Overcoming randomness does not rule out the importance of inherent randomness for functionality. J Biosci. 2019;44:132.
Kenig A, Ilan Y. A personalized signature and chronotherapy-based platform for improving the efficacy of sepsis treatment. Front Physiol. 2019;10:1542.
Khoury T, Ilan Y. Introducing patterns of variability for overcoming compensatory adaptation of the immune system to immunomodulatory agents: a novel method for improving clinical response to anti-TNF therapies. Front Immunol. 2019;10:2726.
El-Haj M, Kanovitch D, Ilan Y. Personalized inherent randomness of the immune system is manifested by an individualized response to immune triggers and immunomodulatory therapies: a novel platform for designing personalized immunotherapies. Immunol Res. 2019;67:337–347.